ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia that are in phase III clinical trials; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ACAD
CUSIPN/A
Phone858-558-2871
Debt
Debt-to-Equity RatioN/A
Current Ratio6.12
Quick Ratio6.02
Price-To-Earnings
Trailing P/E Ratio-9.22
Forward P/E Ratio-10.46
P/E GrowthN/A
Sales & Book Value
Annual Sales$124.90 million
Price / Sales21.78
Cash FlowN/A
Price / CashN/A
Book Value$2.70 per share
Price / Book8.06
Profitability
EPS (Most Recent Fiscal Year)($2.36)
Net Income$-289,400,000.00
Net Margins-135.99%
Return on Equity-78.56%
Return on Assets-68.75%
Miscellaneous
Employees425
Outstanding Shares125,010,000
Market Cap$2.78 billion
ACADIA Pharmaceuticals (NASDAQ:ACAD) Frequently Asked Questions
What is ACADIA Pharmaceuticals' stock symbol?
ACADIA Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACAD."
How were ACADIA Pharmaceuticals' earnings last quarter?
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) issued its quarterly earnings results on Wednesday, August, 8th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.45) by $0.06. The biopharmaceutical company had revenue of $57.06 million for the quarter, compared to analysts' expectations of $58.63 million. ACADIA Pharmaceuticals had a negative return on equity of 78.56% and a negative net margin of 135.99%. The business's revenue for the quarter was up 87.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.55) EPS. View ACADIA Pharmaceuticals' Earnings History.
When is ACADIA Pharmaceuticals' next earnings date?
What price target have analysts set for ACAD?
8 Wall Street analysts have issued twelve-month price objectives for ACADIA Pharmaceuticals' stock. Their forecasts range from $17.00 to $60.00. On average, they anticipate ACADIA Pharmaceuticals' stock price to reach $34.6250 in the next twelve months. This suggests a possible upside of 59.1% from the stock's current price. View Analyst Price Targets for ACADIA Pharmaceuticals.
What is the consensus analysts' recommendation for ACADIA Pharmaceuticals?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ACADIA Pharmaceuticals in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ACADIA Pharmaceuticals.
What are Wall Street analysts saying about ACADIA Pharmaceuticals stock?
Here are some recent quotes from research analysts about ACADIA Pharmaceuticals stock:
- 1. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and raise our 12-month price target to $27 from $25. In August 2018, ACADIA announced a licensing agreement with Neuren Pharmaceuticals (ASX: Rett syndrome. Although this program has yet to take center stage, we believe it is an underappreciated asset that could diversify the pipeline/business strategy over the next 12 months. We recently had an opportunity to meet with Neuren to discuss the history/future of Trofi’." (10/15/2018)
- 2. According to Zacks Investment Research, "Acadia Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. Their three clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson's disease, and ACP-104 and ACP-103, both for the treatment of schizophrenia. " (10/8/2018)
- 3. HC Wainwright analysts commented, "Valuation and risks to achievement of the target price. Our $60 PT is based on an equally weighted composite of: (a) $69/ share, as a 35x multiple of taxed and diluted FY22 GAAP EPS of $4.09 discounted back to and (b) an NPV of $50/share (discount rate 10%, growth rate 2.5%). Risks to our investment thesis and target price include: (1) failure of Nuplazid in further clinical studies; (2) failure of Nuplazid to secure regulatory approval in further indications; and (3) failure of Nuplazid to achieve peak commercial revenue estimates in our model, due to market size, penetration rates, and pricing." (8/9/2018)
Are investors shorting ACADIA Pharmaceuticals?
ACADIA Pharmaceuticals saw a increase in short interest during the month of September. As of September 28th, there was short interest totalling 18,826,968 shares, an increase of 16.5% from the September 14th total of 16,156,517 shares. Based on an average trading volume of 5,629,954 shares, the days-to-cover ratio is presently 3.3 days. Currently, 15.2% of the company's shares are short sold. View ACADIA Pharmaceuticals' Current Options Chain.
Who are some of ACADIA Pharmaceuticals' key competitors?
Some companies that are related to ACADIA Pharmaceuticals include Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Sarepta Therapeutics (SRPT), Genmab A/S (GNMSF), Bausch Health Companies (BHC), Nektar Therapeutics (NKTR), Valeant Pharmaceuticals (VRX), Alnylam Pharmaceuticals (ALNY), Beigene (BGNE), Alkermes (ALKS), Ionis Pharmaceuticals (IONS), Catalent (CTLT), Amarin (AMRN), Dr.Reddy's Laboratories (RDY) and SAGE Therapeutics (SAGE).
Who are ACADIA Pharmaceuticals' key executives?
ACADIA Pharmaceuticals' management team includes the folowing people:
- Mr. Stephen R. Davis, Pres, CEO & Director (Age 57)
- Mr. Todd S. Young, Exec. VP & CFO (Age 46)
- Dr. Srdjan R. Stankovic, Exec. VP and Head of R&D (Age 61)
- Mr. Michael J. Yang, Exec. VP & Chief Commercial Officer (Age 56)
- Mr. Bob Mischler, Sr. VP of Strategy & Technology Operations
Who are ACADIA Pharmaceuticals' major shareholders?
ACADIA Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include Peregrine Capital Management LLC (0.60%), Essex Investment Management Co. LLC (0.03%), NJ State Employees Deferred Compensation Plan (0.03%), Gofen & Glossberg LLC IL (0.01%) and NEXT Financial Group Inc (0.01%). Company insiders that own ACADIA Pharmaceuticals stock include Bros Advisors Lp Baker, Daniel B Soland, Glenn Baity, Laura Brege and Terrence O Moore. View Institutional Ownership Trends for ACADIA Pharmaceuticals.
Which major investors are selling ACADIA Pharmaceuticals stock?
ACAD stock was sold by a variety of institutional investors in the last quarter, including NJ State Employees Deferred Compensation Plan. Company insiders that have sold ACADIA Pharmaceuticals company stock in the last year include Glenn Baity and Laura Brege. View Insider Buying and Selling for ACADIA Pharmaceuticals.
Which major investors are buying ACADIA Pharmaceuticals stock?
ACAD stock was purchased by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Essex Investment Management Co. LLC, Gofen & Glossberg LLC IL and NEXT Financial Group Inc. Company insiders that have bought ACADIA Pharmaceuticals stock in the last two years include Bros Advisors Lp Baker and Daniel B Soland. View Insider Buying and Selling for ACADIA Pharmaceuticals.
How do I buy shares of ACADIA Pharmaceuticals?
Shares of ACAD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ACADIA Pharmaceuticals' stock price today?
One share of ACAD stock can currently be purchased for approximately $21.76.
How big of a company is ACADIA Pharmaceuticals?
ACADIA Pharmaceuticals has a market capitalization of $2.78 billion and generates $124.90 million in revenue each year. The biopharmaceutical company earns $-289,400,000.00 in net income (profit) each year or ($2.36) on an earnings per share basis. ACADIA Pharmaceuticals employs 425 workers across the globe.
What is ACADIA Pharmaceuticals' official website?
How can I contact ACADIA Pharmaceuticals?
ACADIA Pharmaceuticals' mailing address is 3611 VALLEY CENTRE DRIVE SUITE 300, SAN DIEGO CA, 92130. The biopharmaceutical company can be reached via phone at 858-558-2871 or via email at [email protected]
MarketBeat Community Rating for ACADIA Pharmaceuticals (NASDAQ ACAD)
MarketBeat's community ratings are surveys of what our community members think about ACADIA Pharmaceuticals and other stocks. Vote "Outperform" if you believe ACAD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACAD will underperform the S&P 500 over the long term. You may vote once every thirty days.
